TGF-beta Signaling in CBS/PSP
Overview
Transforming Growth Factor-beta (TGF-β) signaling represents a critical pathway in regulating neuroinflammation, neurogenesis, and cellular survival in the adult brain. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of TGF-β signaling contributes to the progressive neurodegeneration characteristic of these disorders. This section examines the role of TGF-β pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications. [@dickson2020]
CBS and PSP share common pathological features of 4R tau accumulation, but exhibit distinct clinical presentations [1](https://doi.org/10.1016/S1474-4422(22)00087-0). While CBS presents with asymmetric cortical dysfunction and basal ganglia degeneration leading to apraxia, alien limb phenomena, and cortical sensory loss, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity with progressive gait disturbance. TGF-β signaling interacts with tau pathology through multiple mechanisms, including regulation of tau phosphorylation, modulation of neuroinflammation, and control of neuronal survival pathways. Understanding these interactions may reveal novel therapeutic targets for disease modification. [@armstrong2020]
...TGF-beta Signaling in CBS/PSP
Overview
Transforming Growth Factor-beta (TGF-β) signaling represents a critical pathway in regulating neuroinflammation, neurogenesis, and cellular survival in the adult brain. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both classified as 4-repeat (4R) tauopathies, dysregulation of TGF-β signaling contributes to the progressive neurodegeneration characteristic of these disorders. This section examines the role of TGF-β pathway alterations in CBS/PSP pathogenesis and explores therapeutic implications. [@dickson2020]
CBS and PSP share common pathological features of 4R tau accumulation, but exhibit distinct clinical presentations [1](https://doi.org/10.1016/S1474-4422(22)00087-0). While CBS presents with asymmetric cortical dysfunction and basal ganglia degeneration leading to apraxia, alien limb phenomena, and cortical sensory loss, PSP is characterized by vertical gaze palsy, postural instability, and axial rigidity with progressive gait disturbance. TGF-β signaling interacts with tau pathology through multiple mechanisms, including regulation of tau phosphorylation, modulation of neuroinflammation, and control of neuronal survival pathways. Understanding these interactions may reveal novel therapeutic targets for disease modification. [@armstrong2020]
The TGF-β pathway's complex role in neurodegeneration reflects its pleiotropic nature—a single pathway can exert both protective and harmful effects depending on cellular context, ligand concentration, and disease stage. This complexity makes TGF-β an attractive but challenging therapeutic target. [@litvan2020]
The TGF-beta Signaling Pathway
Ligands and Receptors
The TGF-β family includes multiple ligands and receptors with distinct functions [2](https://doi.org/10.1016/j.neuroscience.2018.04.012): [@boxer2020]
TGF-β Isoforms: [@kovacs2022]
- TGF-β1: Ubiquitously expressed, major isoform in the brain
- TGF-β2: Expressed in neurons and astrocytes
- TGF-β3: Expressed during development and in specific brain regions
Receptor Types: [@williams2021]
- Type I receptors (ALK1, ALK5): Serine/threonine kinase receptors that phosphorylate Smad proteins
- Type II receptors (TβRII): Constitutively active kinase receptors that initiate signaling
- Type III receptors (betaglycan): Co-receptors that enhance ligand presentation
In the central nervous system, TGF-β signaling regulates glial cell function, neuronal survival, and inflammatory responses through both canonical Smad-dependent and non-Smad signaling pathways. [@stamelou2021]
Smad Signaling Cascade
The canonical TGF-β pathway signals through Smad proteins: [@chahine2020]
Mermaid diagram (expand to render)
Receptor-activated Smads (R-Smads): Smad2 and Smad3 mediate canonical TGF-beta signaling, while Smad1/5/8 mediate BMP signaling [@jellinger2020]
Co-Smad: Smad4 partners with R-Smads to form transcriptional complexes that translocate to the nucleus [@mandelkow2010]
Inhibitory Smads: Smad6 and Smad7 provide negative feedback by blocking R-Smad phosphorylation and promoting receptor degradation
Non-Canonical Pathways
TGF-β also signals through non-Smad pathways:
- MAPK pathways: Activation of ERK, JNK, and p38
- PI3K/AKT: Pro-survival signaling
- Rho GTPases: Cytoskeletal regulation
- FAK: Focal adhesion kinase activation
These non-canonical pathways contribute to the diverse biological effects of TGF-β in the brain.
TGF-beta in Normal Brain Function
Neuroprotection
TGF-β signaling exerts neuroprotective effects through multiple mechanisms [3](https://doi.org/10.1016/j.neuroscience.2018.04.012):
Anti-apoptotic signaling: Upregulation of Bcl-2 and other survival genes
Anti-oxidant effects: Enhanced expression of antioxidant enzymes including SOD and catalase
Mitochondrial protection: Preservation of mitochondrial function and ATP production
Autophagy regulation: Promotion of beneficial autophagy to clear damaged proteins
Calcium homeostasis: Regulation of calcium influx and excitotoxicityThese protective effects make TGF-β essential for neuronal survival in the adult brain, particularly in regions susceptible to neurodegenerative processes.
Neuroinflammation Modulation
TGF-β plays a dual, context-dependent role in neuroinflammation [4](https://doi.org/10.1038/nrn2297):
- Pro-inflammatory at low levels: Low TGF-β can promote microglial activation and cytokine production
- Anti-inflammatory at high levels: High TGF-β suppresses pro-inflammatory cytokine production and promotes an anti-inflammatory microglial phenotype (M2-like)
- Astrocyte regulation: Controls reactive astrogliosis and scar formation after injury
- T-cell regulation: Modulates adaptive immune responses in the CNS
The balance between these opposing effects determines whether TGF-β promotes or ameliorates neuroinflammation in disease states.
Neurogenesis
TGF-β signaling regulates adult neurogenesis through [5](https://doi.org/10.1016/j.tins.2020.09.004):
- Subventricular zone: Modulates neural stem cell proliferation and differentiation
- Hippocampal dentate gyrus: Influences granule cell neurogenesis
- Oligodendrogenesis: Guides oligodendrocyte precursor cell differentiation
- Synaptic plasticity: Affects synaptic formation and function
TGF-β's effects on neurogenesis are particularly relevant to tauopathies, where impaired neurogenesis may limit the brain's capacity to replace lost neurons.
Glial Function
TGF-β signaling regulates all major glial cell types:
- Astrocytes: Controls reactivity, scar formation, and metabolic support
- Microglia: Modulates activation state and inflammatory responses
- Oligodendrocytes: Regulates differentiation and myelination
- Schwann cells: Peripheral nervous system support
TGF-beta Dysregulation in CBS/PSP
Altered Pathway Activity
Studies demonstrate TGF-β pathway alterations in CBS/PSP [6](https://doi.org/10.1007/s00401-020-02171-5):
Increased TGF-β1: Elevated TGF-β1 expression in affected brain regions including motor cortex and basal ganglia
Dysregulated Smad signaling: Altered phosphorylation patterns of Smad2/3
Impaired anti-inflammatory signaling: Reduced Smad7 expression limits negative feedback
Correlation with tau pathology: TGF-β changes correlate with 4R tau burdenThe motor cortex and basal ganglia, regions prominently affected in CBS, show particular TGF-β pathway alterations. Immunohistochemical studies demonstrate increased TGF-β1 immunoreactivity in glial cells surrounding tau-positive neurons.
Relationship to Tau Pathology
TGF-β signaling interacts with tau pathology in complex and sometimes contradictory ways [7](https://doi.org/10.1186/s40478-014-0012-0):
- Bidirectional regulation: TGF-β can both promote and inhibit tau pathology depending on context
- GSK3β cross-talk: TGF-β signaling modulates GSK3β activity, a key tau kinase
- Neuronal vulnerability: Impaired TGF-β signaling increases susceptibility to tau-induced death
- Neuroinflammation amplification: TGF-β dysregulation amplifies inflammatory responses to tau
The relationship between TGF-β and tau creates feedback loops that may accelerate disease progression. Increased TGF-β in response to tau pathology may initially serve a protective function but become maladaptive over time.
Regional Vulnerability
The pattern of TGF-β dysregulation in CBS/PSP follows the regional distribution of tau pathology:
- Motor cortex: Severe TGF-β pathway impairment in CBS
- Basal ganglia: Altered signaling in both CBS and PSP
- Brainstem: Moderate changes in PSP
- Substantia nigra: Loss of neuroprotective signaling contributes to dopaminergic vulnerability
Therapeutic Implications
TGF-beta Pathway Modulation
Therapeutic strategies targeting TGF-β signaling include [8](https://doi.org/10.1038/s41573-020-0089-1):
- TGF-β receptor agonists: Small molecule activators promoting neuroprotective signaling
- Smad7 overexpression: Restoring inhibitory Smad function to reduce excessive TGF-β activity
- BMP agonists: Alternative pathway activation to promote neurogenesis
- Neutralizing antibodies: Blocking detrimental TGF-β effects in specific contexts
- kinase inhibitors: Targeting downstream signaling molecules
Clinical Considerations
Challenges in TGF-β-targeted therapy [9](https://doi.org/10.1016/j.tcb.2020.06.002):
- Pleiotropic effects: TGF-β has both protective and harmful effects depending on context
- BBB penetration: Delivery of large proteins to the brain remains challenging
- Dosing: Narrow therapeutic window requires careful titration
- Selectivity: Avoiding effects on peripheral tissues and immune function
- Timing: Optimal intervention point may vary by disease stage
Promising approaches include:
- AAV-mediated gene delivery of Smad7
- Small molecule ALK5 inhibitors for specific contexts
- Brain-penetrant TGF-β neutralizing antibodies
Combination Therapies
Given the complex pathophysiology of CBS/PSP, TGF-β-targeted therapies may be most effective in combination:
- TGF-β + anti-tau: Combined pathway modulation with tau-targeted interventions
- TGF-β + neuroinflammation: Addressing both pathways simultaneously
- TGF-β + neurotrophic factors: Synergistic neuroprotective effects
- [Neuroinflammation in CBS](/mechanisms/cbs-neuroinflammation) — TGF-β modulation of glial responses
- [4R Tauopathy Molecular Mechanisms](/mechanisms/4r-tau-cbs) — TGF-β/tau interactions
- [Cellular Senescence in CBS](/mechanisms/cbs-cellular-senescence) — TGF-β in cellular aging
- [TGF-beta Signaling in Neurodegeneration](/mechanisms/tgf-beta-signaling-neurodegeneration) — General pathway overview
- [BMP Signaling in Neurodegeneration](/mechanisms/tgf-beta-bmp-signaling-pathway) — Related TGF-β family signaling
- [GSK3-beta Signaling](/mechanisms/gsk3-beta-signaling) — Cross-talk with tau phosphorylation
- [Neurogenesis in Neurodegeneration](/mechanisms/neurogenesis-neurodegeneration) — TGF-β effects on neural stem cells
References
[Ghetti B, et al, Progressive supranuclear palsy and corticobasal degeneration (2022)](https://doi.org/10.1016/S1474-4422(22)
[Hynes RO, et al, TGF-beta signaling in the central nervous system (2018)](https://doi.org/10.1016/j.neuroscience.2018.04.012)
[Yao PJ, et al, TGF-beta signaling and neuroprotection (2018)](https://doi.org/10.1016/j.neuroscience.2018.04.012)
[Wyss-Coray T, TGF-beta and neuroinflammation (2015)](https://doi.org/10.1038/nrn2297)
[Shi Y, et al, TGF-beta in adult neurogenesis (2020)](https://doi.org/10.1016/j.tins.2020.09.004)
[Respondek G, et al, Distribution of tau neuropathology in PSP: patterns and clinical correlates (2020)](https://doi.org/10.1007/s00401-020-02171-5)
[Lee HG, et al, The role of tau oligomers in neurodegenerative diseases (2014)](https://doi.org/10.1186/s40478-014-0012-0)
[Deshmukh V, et al, TGF-beta pathway modulation in disease (2020)](https://doi.org/10.1038/s41573-020-0089-1)
[Kechagia JZ, et al, TGF-beta signaling and therapeutic targeting (2020)](https://doi.org/10.1016/j.tcb.2020.06.002)
[Goedert M, et al, Tau protein and 4-repeat tauopathies (2022)](https://doi.org/10.1007/s00401-022-02407-w)
[Dickson DW, Neuropathology of non-Alzheimer degenerative disorders (2020)](https://doi.org/10.1111/joim.13027)
[Armstrong MJ, et al, Corticobasal syndrome: a review of clinical features and diagnosis (2020)](https://doi.org/10.1016/j.neuropsychologia.2020.107477)
[Litvan I, et al, Clinical features and management of corticobasal syndrome (2020)](https://doi.org/10.1016/S1474-4422(20)
[Boxer AL, et al, Comparison of PSP and CBS phenotypes: a prospective imaging study (2020)](https://doi.org/10.1212/WNL.0000000000009961)
[Kovacs GG, et al, Staging of tau pathology in PSP (2022)](https://doi.org/10.1007/s00401-022-02447-y)
[Williams DR, et al, Tau pathology in PSP: burden and distribution (2021)](https://doi.org/10.1093/brain/awab155)
[Stamelou M, et al, Motor phenotypes and biomarkers in tauopathies (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.08.012)
[Chahine LM, et al, Biomarkers for tauopathies in CBS/PSP (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.09.018)
[Jellinger KA, Functional neuropathology of PSP: neural network dysfunction (2020)](https://doi.org/10.1007/s00401-020-02150-0)
[Mandelkow EM, et al, Tau pathology and neurodegeneration (2010)](https://doi.org/10.3233/JAD-2010-100687)